News Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Delayed OTC Markets Other stock markets 09:49:20 02/05/2024 pm IST			5-day change	1st Jan Change
0.0113 ^USD	+0.36%		+88.33%	-94.21%

21/03	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
20/03	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	22/03	CI
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	20/03	CI
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from NASDAQ Composite Index	15/03	CI
Sector Update: Health Care Stocks Lower Thursday Afternoon	14/03	MT
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	14/03	MT
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	14/03	BU
Better Therapeutics : Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Form 8-K	14/03	PU
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	05/03	BU
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	04/03	BU
Transcript: Better Therapeutics CEO Interview with RedChip - Form 8-K	04/03	PU
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	20/02	MT
Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform	20/02	DJ
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20/02	BU
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20/02	CI
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment	06/02	BU
Better Therapeutics, Inc. announced that it has received $0.25 million in funding	23/01	CI
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone	17/01	BU
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	17/01	CI
Better Therapeutics, Inc. announced that it expects to receive $0.25 million in funding	05/01	CI
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	03/01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Summary

Filters